# Moderate - Severe Degenerative Disc Disease Evaluation of the Lumbar Spine

> **NCT05516992** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Spine BioPharma, Inc** · enrollment: 417 (actual)

## Conditions studied

- Lumbar Degenerative Disc Disease

## Interventions

- **DRUG:** SB-01 For Injection
- **DRUG:** Sham Needle

## Key facts

- **NCT ID:** NCT05516992
- **Lead sponsor:** Spine BioPharma, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-08-19
- **Primary completion:** 2025-03-21
- **Final completion:** 2025-08-27
- **Target enrollment:** 417 (ACTUAL)
- **Last updated:** 2025-06-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05516992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05516992, "Moderate - Severe Degenerative Disc Disease Evaluation of the Lumbar Spine". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05516992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*